



Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi - 221 005

CERTIFICATE

It is certified that the work contained in the thesis titled
***“COMBINATION STRATEGIES FOR ENHANCING ANTI-TUMOR
ACTIVITY OF ANTI-PD1 MONOCLONAL ANTIBODY”*** by
GULLANKI NAGA VENKATA CHARAN TEJ has been carried out under
my supervision and that this work has been not submitted elsewhere for a
degree.

It is further certified that the student has fulfilled all the requirements
of Course work, Comprehensive, Candidacy, SOTA and Pre-submission
seminar.

Dr. Prasanta Kumar Nayak

Department of Pharmaceutical Engineering & Technology

Indian Institute of Technology (BHU), Varanasi

डॉ० प्रसान्त कुमार नायक / Dr. Prasanta Kumar Nayak
सहायक आचार्य / Assistant Professor
भैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी-२२१००५ / Varanasi-221005
E-mail: gsnayak.phe@iitbhu.ac.in



Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi - 221 005

DECLARATION BY THE CANDIDATE

I, **Gullanki Naga Venkata Charan Tej**, certify that the work embodied in this Ph.D. thesis is my own bonafide work and carried out by me under the supervision of **Dr. Prasanta Kumar Nayak** from **July, 2016 to August, 2021** at the **Department of Pharmaceutical Engineering & Technology**, Indian Institute of Technology (B.H.U.), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma.

I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in this thesis. I further declare that I have not willfully copied any other's work, paragraphs, text, data, results, etc., reported in journals, books, magazines, reports, dissertations, theses, etc., or available at websites and have not included them in this Ph.D. thesis and have not cited as my own work.

Date: 04/04/2022
Place: Varanasi

G. N. V. Charan Tej
(Gullanki Naga Venkata Charan Tej)

CERTIFICATE FROM THE SUPERVISOR

It is certified that the above statement made by the student is correct to the best of my/our knowledge.


Dr. Prasanta Kumar Nayak / Dr. Prasanta Kumar Nayak
(Dr. Prasanta Kumar Nayak) Professor
विश्वभारती विश्वविद्यालय एवं प्रौद्योगिकी विभाग
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी-221005 / Varanasi-221005
E-mail: pknayak.phe@iitbhu.ac.in

S. Hemalatha 4/4/22
(Prof. S. Hemalatha)
Head of the Department
विभागाध्यक्ष / Head
आरोग्य अभियंता एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी-221005 / Varanasi-221005



Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi - 221 005

COPYRIGHT TRANSFER CERTIFICATE

Title of the Thesis: "COMBINATION STRATEGIES FOR ENHANCING ANTI-TUMOR ACTIVITY OF ANTI-PD1 MONOCLONAL ANTIBODY"

Name of the Student: Mr. GULLANKI NAGA VENKATA CHARAN TEJ

Copyright Transfer

The undersigned hereby assigns to the Indian Institute of Technology (B.H.U.), Varanasi all rights under copyright that may exist in and for the above thesis submitted for the award of the "*Doctor of Philosophy*".

Date: 04/04/2022

G. N. V. Charan Tej
(Gullanki Naga Venkata Charan Tej)

Place: Varanasi

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author's personal use provided that the source and the Institute's copyright notice are indicated.

Acknowledgements

The satisfaction and pleasure that accompany the successful completion of my research work is incomplete without expressing gratitude to those who did their level best by contributing in their own ways.

With a profound sense of gratitude, I would like to pay my tribute to the founder of Banaras Hindu University, Bharat Ratna Pandit Madan Mohan Malaviya Ji, who made this glorious place as the capital of education.

I am deeply indebted thankful to my esteemed supervisor Dr Prasanta Kumar Nayak, Assistant Professor of Pharmacology, Department of Pharmaceutical Engineering and Technology (Banaras Hindu University), Varanasi, whose benevolent support, constant inspiration, insurmountable guidance and unending enthusiasm, enabled me to complete my research work smoothly. He has always been a constant source of encouragement and patient bearer of my mistakes. I feel very much honored and it has been a real privilege for me to get an opportunity to work under him.

I am obliged and also thankful to Prof. S. Hemalatha, Head, Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi for providing facilities for my research work. I am obliged to all RPEC and DPGC members for evaluation of my research work.

I am immensely thankful to all respected faculty members Prof. Sairam Krishnamurthy, Prof. Brahmeshwar Mishra, Prof. Sushil Kumar Singh, Prof. Sanjay Singh, Prof. Sushant Kumar Shrivastava, Dr. Anand Kumar Srivastava, Siva, Dr. Senthil Raja Ayyannan, Dr. Ashok Kumar, Dr. Alakh Niranjana Sahu, Dr. (Mrs.) Ruchi Chawla, Dr. Sunil Kumar Mishra, Dr. Gyan Prakash Modi, Dr. Madaswamy Sona Muthu, Dr. Shreyans Kumar Jain, Dr. Ashish Kumar Agrawal, and Dr. Vinod Tiwari for their co-operation & valuable suggestions during my research work.

I am grateful to the Indian Institute of Technology (Banaras Hindu University), Varanasi for providing financial assistance in the form of teaching assistantship.

I wish to express a special word of thanks to Dr. Naveen Shivavedi, Mr. Mukesh Kumar budani and Mr. Kaushik Neogi for all the moral, social, and technical support during my research work and all research scholars of the Department and junior fellows for their continuous support.

My personal appreciation and heartfelt thanks goes to my seniors and dear friends Mr. Satish Thokla, Mr. Gopichand Gutti, Mr. Ramakrishna K, Mr. Kasi Vishwanadh, Mr. Yash Pal singh, Mr. Ankit, Mr. Qadir, Mr. Vishwanadh Shukla, Mr. Jitender, Mr. Sumit Kumar, Mr. Himanshu Verma and Mr. Venkateswarlu.

I would also like to deliver my warm thanks to all the supporting staff of the department specially Mr. Ram Jiyawan, Mr. Yashwant Singh, Mr. Atul Kumar Gupta, Mr. Anand Kumar, Md. Rafique Ji, Md. Jameel Ji, Mr. Nand Lal, Mr. Ram Hriday Pathak, and Mr. Amit Kumar for their technical assistance and co-operation throughout my dissertation work. Without their invaluable support I was unable to fulfill my work properly.

Finally, I would like to express my heartiest and sincere regards to my whole family, specially my admirable mother, awesome father, loving brother and splendid sister, whose constant love, moral support, and blessings have encouraged me more and more to prosper during my studies which enabled me to reach this height in the journey of existence. With deepest gratitude and love, I bow down at the lotus feet of lord Vishwanathji, for never leaving me alone during the times of trials and suffering and molding me in to what I am today

I take great privilege to express my heartfelt thanks to all those who have directly or indirectly helped me get through this research work successfully.

Date: 04-04-2022
Place: IIT (BHU), Varanasi

G.N.V. Charan Tej
(G.N.V. Charan Tej)

Table of Contents

Certificate.....	ii
Declaration by the candidate.....	iii
Copyright transfer certificate.....	iv
Acknowledgements.....	v
Table of Contents	vii
List of Figures.....	xi
List of Tables.....	xiii
List of Abbreviations.....	xv
Preface.....	xvii
1. Chapter 1: General Introduction.....	1
1.1. Introduction.....	2
1.2. Prevalence.....	2
1.3. Pathophysiology.....	3
1.4. Hallmarks of cancer.....	4
1.4.1. Sustaining proliferative signaling.....	4
1.4.2. Resisting cell death.....	5
1.4.3. Evading growth suppressors.....	6
1.4.4. Enabling replicative immortality.....	6
1.4.5. Inducing angiogenesis.....	7
1.4.6. Tissue invasion and metastasis.....	8
1.4.7. Emerging hallmark: Reprogramming energy metabolism.....	9
1.4.8. Emerging Hallmark: Evading immune destruction.....	10
1.4.8.1 Factors that tumors exploit to avoid immune responses	11
1.5. Management and treatment.....	12
1.5.1. Surgery.....	12
1.5.2. Chemotherapy.....	13
1.5.3. Radiotherapy.....	13
1.5.4. Immunotherapy.....	14
1.5.4.1 Safety and toxicology of immune checkpoint inhibitors.....	15
1.6. Caffeine.....	15
1.6.1. Effect of caffeine on cell cycle progression.....	16
1.6.2. Effect of caffeine on apoptosis.....	17

1.6.3.	Effect of caffeine on drug efflux.....	19
1.6.4.	Effect of caffeine on anti-tumor immunity.....	21
1.6.5.	Effect of caffeine on tumor angiogenesis.....	23
1.7.	Oxaliplatin.....	24
1.7.1.	Immunologic Mechanisms: Immunogenic Cell Death (ICD).....	25
1.8.	Aims.....	26
1.9.	Hypothesis.....	27
2.	Chapter 2: Evaluation of antitumor immune response of caffeine and anti-PD1 monoclonal antibody combination against carcinogen and cell line induced tumors in mice.....	30
2.1.	Introduction.....	31
2.2.	Materials and methods.....	32
2.2.1.	Animals.....	32
2.2.2.	Drugs, Chemicals and Antibodies.....	32
2.2.3.	Carcinogen-induced tumor model.....	33
2.2.4.	Caffeine treatment protocol.....	33
2.2.5.	Body, heart, liver and kidney weight measurement.....	34
2.2.6.	Flow cytometric analysis of tumor infiltrating lymphocytes.....	34
2.2.7.	Analysis of intratumoral levels of TNF- α and IFN- γ by ELISA.....	34
2.2.8.	Histopathological analysis of tumor tissue.....	35
2.2.9.	Statistical analysis.....	35
2.3.	Results.....	35
2.3.1.	Effect of caffeine on tumor incidence and growth.....	35
2.3.2.	Effect of caffeine on anti-tumor immune response.....	37
2.3.3.	Effect of caffeine on infiltration of T-lymphocytes.....	38
2.3.4.	Effect of caffeine on infiltration of CD8 ⁺ and CD4 ⁺ CD25 ⁺ regulatory T cells.....	40
2.3.5.	Effect of caffeine on expression of PD-1 on CD8 ⁺ and CD4 ⁺ CD25 ⁺ regulatory T cells.....	41
2.3.6.	Effect of caffeine on intratumoral levels of TNF- α and IFN- γ	41
2.3.7.	Effect of caffeine on body, heart, liver and kidney weights.....	42
2.4.	Discussion.....	43
2.5.	Conclusion.....	44
3.	Chapter 3: Evaluation of antitumor immune response of caffeine and anti-PD1 monoclonal antibody combination against carcinogen and cell line induced tumors in mice.....	46

3.1. Introduction.....	47
3.2. Materials and methods.....	47
3.2.1. Animals.....	47
3.2.2. Cell line, Drugs and Chemicals.....	48
3.2.3. Carcinogen-induced tumor model.....	48
3.2.4. Cell line-induced tumor model.....	48
3.2.5. Tumor measurement and survival analysis.....	49
3.2.6. Body, heart, liver and kidney weight measurement.....	49
3.2.7. Flow cytometric analysis of tumor infiltrating lymphocytes.....	49
3.2.8. Analysis of intratumoral levels of TNF- α and IFN- γ by ELISA.....	50
3.2.9. Statistical analysis.....	50
3.3. Results.....	50
3.3.1. Effects of caffeine, anti-PD1 mAb, or their combination on tumor progression and survival in carcinogen-induced tumor model.....	50
3.3.2. Effects of caffeine, anti-PD1 mAb, or their combination on tumor progression and survival in cell line-induced tumor model.....	52
3.3.3. Effects of caffeine, anti-PD1 mAb or their combination on T-lymphocyte infiltration into cell line-induced tumors.....	54
3.3.4. Effects of caffeine, anti-PD1 mAb or their combination on CD4 T-lymphocyte infiltration into cell line-induced tumors.....	55
3.3.5. Effects of caffeine, anti-PD1 mAb or their combination on CD8 T-lymphocyte infiltration into cell line-induced tumors.....	56
3.3.6. Effects of caffeine, anti-PD1 mAb or their combination on CD4+ CD25+ T-lymphocyte infiltration into cell-line induced tumors.....	57
3.3.7. Effects of caffeine or anti-PD1 mAb or their combination on intratumoral levels of TNF- α and IFN- γ	58
3.3.8. Effect of caffeine or anti-PD1 mAb or their combination on body, heart, liver and kidney weights.....	59
3.4. Discussion.....	59
3.5. Conclusion.....	62
4. Chapter 3: Evaluation of antitumor immune response of oxaliplatin and anti-PD1 monoclonal antibody combination against carcinogen and cell line induced tumors in mice.....	63
4.1. Introduction.....	64
4.2. Materials and methods.....	64
4.2.1. Animals.....	64
4.2.2. Cell line, Drugs and Chemicals.....	65
4.2.3. Carcinogen-induced tumor model.....	65
4.2.4. Cell line-induced tumor model.....	65

4.2.5. Tumor measurement.....	66
4.2.6. Body, heart, liver and kidney weight measurement.....	66
4.2.7. Flow cytometric analysis of tumor infiltrating lymphocytes.....	66
4.2.8. Analysis of intratumoral levels of TNF- α and IFN- γ by ELISA.....	67
4.2.9. Statistical analysis.....	67
4.3. Results.....	67
4.3.1. Effects of oxaliplatin, anti-PD1 mAb, or their combination on tumor progression and survival in carcinogen-induced tumor model.....	67
4.3.2. Effects of oxaliplatin, anti-PD1 mAb, or their combination on tumor progression and survival in cell line-induced tumor model.....	69
4.3.3. Effects of oxaliplatin, anti-PD1 mAb or their combination on CD4 T-lymphocyte infiltration into cell line-induced tumors.....	71
4.3.4. Effects of oxaliplatin, anti-PD1 mAb or their combination on CD4 8-lymphocyte infiltration into cell line-induced tumors.....	71
4.3.5. Effects of oxaliplatin, anti-PD1 mAb or their combination DAMPs.....	72
4.3.6. Effects of oxaliplatin or anti-PD1 mAb or their combination on intratumoral levels of TNF- α and IFN- γ	73
4.3.7. Effect of oxaliplatin or anti-PD1 mAb or their combination on body, heart, liver and kidney weights.....	74
4.4. Discussion.....	76
4.5. Conclusions.....	78
5. Chapter 5: Discussion and conclusions.....	79
5.1. Summary of major findings.....	84
5.2. Scope for further work.....	85
6. Chapter 6: References.....	87

List of Figures

Figure 1.1: Effect of caffeine on cell cycle progression.....	16
Figure 1.2: Effect of caffeine on apoptosis.....	18
Figure 1.3: Effect of caffeine on drug uptake.....	20
Figure 1.4: Effect of caffeine on anti – tumor immunity	22
Figure 1.5: Effect of caffeine on tumor angiogenesis.....	23
Figure 1.6: Mechanism of caffeine and anti-PD1 induced antitumor immune response...	27
Figure 1.7: Mechanism of oxaliplatin and anti-PD1 induced antitumor immune response.....	28
Figure 2.1: Mechanism of caffeine induced antitumor immune response.....	31
Figure 2.2: Caffeine treatment decreased carcinogen-induced tumor incidence.....	34
Figure 2.3: Caffeine treatment decreased the rate of carcinogen-induced tumor growth...	35
Figure 2.4: Caffeine treatment is associated with increased leucocytes infiltration in carcinogen-induced tumors	36
Figure 2.5: Caffeine treatment increased T lymphocyte infiltration in carcinogen-induced tumors.....	37
Figure 2.6: Caffeine treatment increased T lymphocyte infiltration in carcinogen-induced tumors- Flow cytometric results.....	38
Figure 2.7: Caffeine treatment increased TNF- α and IFN- γ levels in carcinogen-induced tumors	40
Figure 3.1: Combination of caffeine and anti-PD1 mAb inhibited the carcinogen-induced tumor growth.....	49
Figure 3.2: Caffeine and anti-PD1 mAb combination therapy increased the overall survival period in carcinogen-induced tumor model	50
Figure 3.3: Caffeine and anti-PD1 mAb combination therapy inhibited cell line-induced tumor growth	51
Figure 3.4: Caffeine and anti-PD1 mAb combination therapy increased the T lymphocyte infiltration into cell line-induced tumors	52
Figure 3.5: Caffeine and anti-PD1 mAb combination therapy increased the CD4 T-lymphocyte infiltration into cell line-induced tumors	53
Figure 3.6: Caffeine and anti-PD1 mAb combination therapy increased the CD4 T-lymphocyte infiltration into cell line-induced tumors.....	54

Figure 3.7: Caffeine and anti-PD1 mAb combination therapy decreased the infiltration of CD4+ CD25+ T-lymphocytes in cell line-induced tumor model	55
Figure 3.8: Caffeine and anti-PD1 mAb combination therapy increased the intratumoral levels of TNF- α and IFN- γ	56
Figure 4.1: Combination of oxaliplatin and anti-PD1 mAb inhibited the carcinogen-induced tumor growth	66
Figure 4.2: Combination of oxaliplatin and anti-PD1 mAb increased the overall survival period in carcinogen-induced tumor model	67
Figure 4.3: Oxaliplatin and anti-PD1 mAb combination therapy inhibited cell line-induced tumor growth	68
Figure 4.4: Effects of oxaliplatin, anti-PD1 mAb or their combination on CD4 T lymphocytes into cell line-induced tumor model	69
Figure 4.5: Effects of oxaliplatin, anti-PD1 mAb or their combination on CD8 T lymphocytes into cell line-induced tumor model.....	70
Figure 4.6: Effects of oxaliplatin, anti-PD1 mAb or their combination on DAMPs.....	71
Figure 4.7: Effects of oxaliplatin, anti-PD1 mAb or their combination on intra-tumoral levels of TNF- α and IFN- γ	72

List of Tables

Table 1: Effect of caffeine on body weight.....	40
Table 2: Effect of caffeine on major organs.....	41
Table 3: Effect of caffeine, anti-PD1 or their combination on body weight of mice with carcinogen induced tumors	57
Table 4: Effect of caffeine, anti-PD1 or their combination on body weight of mice with B16F10 melanoma induced tumors	57
Table 5: Effect of caffeine, anti-PD1 or their combination on major organs of mice with carcinogen induced tumors	58
Table 6: Effect of caffeine, anti-PD1 or their combination on major organs of mice B16F10 melanoma induced tumors	58
Table 7: Effect of oxaliplatin, anti-PD1 or their combination on body weight of mice with carcinogen induced tumors	73
Table 8: Effect of oxaliplatin, anti-PD1 or their combination on body weight of mice with B16F10 melanoma induced tumors	73
Table 9: Effect of oxaliplatin, anti-PD1 or their combination on major organs of mice with carcinogen induced tumors	74
Table 10: Effect of oxaliplatin, anti-PD1 or their combination on major organs of mice with B16F10 melanoma induced tumors	74

List of Abbreviations

Abbreviations	Full forms
A2A	Adenosine 2A
ANOVA	Analysis of Variance
CAMs	Cellular Adhesion Molecules
ELISA	Enzyme Linked Immunosorbent Assay
FDA	Food and Drug Administration
HIF	Hypoxia Inducible Factor
K _i	Inhibitory constant
TILs	Tumor infiltrating lymphocytes
PD-1	Programmed cell death protein 1
PD-L1	Programmed cell death ligand 1
CTLA4	Cytotoxic T-lymphocyte associated protein 4
MCA	Methylcholanthrene
NO	Nitric oxide
WHO	World Health Organization
VEGF	Vascular Endothelial Growth Factor
DAMPs	Damage associated molecular patterns
HMGB1	High mobility group box 1
TNF- α	Tumor necrosis factor alpha
IFN- γ	Interferon gamma 1